{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/unlocking-cns-insights-continuous-csf-sampling-first-human-alzheimers-trials#webpage",
"url": "https://www.fortrea.com/insights/unlocking-cns-insights-continuous-csf-sampling-first-human-alzheimers-trials",
"name": "Unlocking CNS insights: Continuous CSF sampling in first-in-human Alzheimer’s trials",
"description": "This Fortrea case study highlights how continuous cerebrospinal fluid (CSF) sampling was successfully implemented in a first-in-human Alzheimer's clinical trial to provide dynamic insights into central nervous system (CNS) biomarkers and support early development decision-making. The sponsor required early biomarker readouts for Aβ, tau, and PK/PD assessments to evaluate CNS penetration, mechanism of action, and biomarker kinetics, while managing the operational complexity associated with invasive lumbar catheter procedures and extended collection windows. Fortrea addressed these challenges through in-house procedural delivery, continuous CSF collection workflows, participant-focused operational practices, and integration of CSF sampling within existing early-phase clinical operations. By enabling both continuous and protocol-defined single-timepoint sampling approaches, the study generated more comprehensive biomarker data than traditional collection methods, reduced variability in PK/PD modeling inputs, improved understanding of biomarker movement and exposure-response relationships, and maintained strong participant tolerability throughout the study. The case study demonstrates how continuous CSF sampling can enhance CNS biomarker assessment, strengthen early-phase evidence generation, and accelerate decision-making in Alzheimer's disease drug development and broader CNS clinical research programs."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Unlocking CNS insights: Continuous CSF sampling in first-in-human Alzheimer’s trials",
"item": "https://www.fortrea.com/insights/unlocking-cns-insights-continuous-csf-sampling-first-human-alzheimers-trials"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/unlocking-cns-insights-continuous-csf-sampling-first-human-alzheimers-trials#casestudy",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/unlocking-cns-insights-continuous-csf-sampling-first-human-alzheimers-trials#webpage"
},
"headline": "Continuous CSF Sampling: Unlocking CNS Biomarker Insights in First-in-Human Alzheimer's Trials | Fortrea Case Study",
"description": "This Fortrea case study highlights how continuous cerebrospinal fluid (CSF) sampling was successfully implemented in a first-in-human Alzheimer's clinical trial to provide dynamic insights into central nervous system (CNS) biomarkers and support early development decision-making. The sponsor required early biomarker readouts for Aβ, tau, and PK/PD assessments to evaluate CNS penetration, mechanism of action, and biomarker kinetics, while managing the operational complexity associated with invasive lumbar catheter procedures and extended collection windows. Fortrea addressed these challenges through in-house procedural delivery, continuous CSF collection workflows, participant-focused operational practices, and integration of CSF sampling within existing early-phase clinical operations. By enabling both continuous and protocol-defined single-timepoint sampling approaches, the study generated more comprehensive biomarker data than traditional collection methods, reduced variability in PK/PD modeling inputs, improved understanding of biomarker movement and exposure-response relationships, and maintained strong participant tolerability throughout the study. The case study demonstrates how continuous CSF sampling can enhance CNS biomarker assessment, strengthen early-phase evidence generation, and accelerate decision-making in Alzheimer's disease drug development and broader CNS clinical research programs.",
"genre": "Case Study",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2026-02/continuous-csf-alzheimers-trials.png.jpg"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2026-02-11",
"dateModified": "2026-02-11",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2026-02/continuous-csf-alzheimers-trials.pdf.pdf",
"encodingFormat": "application/pdf"
}
}
]
}